Regeneron, Sanofi Present Positive Results from Pivotal Phase 3 Study of Sarilumab at ACR Annual Meeting

By: via Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) today announced results from a pivotal Phase 3 study of sarilumab, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.